Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Pemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characterization of autoantibodies and autoreactive B cells, and elucidation of cell–cell adhesion between keratinocytes. For the management of pemphigus and pemphigoid, the administration of systemic corticosteroids still represents the standard treatment strategy; however, evidence of the efficacy of therapies not involving corticosteroids, such as those employing anti-CD20 antibodies, is increasing. The goal should be to develop antigen-specific immune suppression-based treatments.

Original languageEnglish
Article number1360
JournalF1000Research
Volume7
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Bullous Pemphigoid
Pemphigus
Autoantibodies
Adrenal Cortex Hormones
Erosion
Skin
Adhesion
Immunoglobulin G
Cells
Blister
Keratinocytes
Antigens
Autoimmune Diseases
Antibodies
Anti-Idiotypic Antibodies
Mucous Membrane
B-Lymphocytes
Therapeutics

Keywords

  • Pemphigoid
  • Pemphigus

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees : 2 approved]. / Yamagami, Jun.

In: F1000Research, Vol. 7, 1360, 01.01.2018.

Research output: Contribution to journalReview article

@article{08ee5393d4004accba5dc12f23c7fc9d,
title = "Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]",
abstract = "Pemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characterization of autoantibodies and autoreactive B cells, and elucidation of cell–cell adhesion between keratinocytes. For the management of pemphigus and pemphigoid, the administration of systemic corticosteroids still represents the standard treatment strategy; however, evidence of the efficacy of therapies not involving corticosteroids, such as those employing anti-CD20 antibodies, is increasing. The goal should be to develop antigen-specific immune suppression-based treatments.",
keywords = "Pemphigoid, Pemphigus",
author = "Jun Yamagami",
year = "2018",
month = "1",
day = "1",
doi = "10.12688/f1000research.14474.1",
language = "English",
volume = "7",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees

T2 - 2 approved]

AU - Yamagami, Jun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Pemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characterization of autoantibodies and autoreactive B cells, and elucidation of cell–cell adhesion between keratinocytes. For the management of pemphigus and pemphigoid, the administration of systemic corticosteroids still represents the standard treatment strategy; however, evidence of the efficacy of therapies not involving corticosteroids, such as those employing anti-CD20 antibodies, is increasing. The goal should be to develop antigen-specific immune suppression-based treatments.

AB - Pemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characterization of autoantibodies and autoreactive B cells, and elucidation of cell–cell adhesion between keratinocytes. For the management of pemphigus and pemphigoid, the administration of systemic corticosteroids still represents the standard treatment strategy; however, evidence of the efficacy of therapies not involving corticosteroids, such as those employing anti-CD20 antibodies, is increasing. The goal should be to develop antigen-specific immune suppression-based treatments.

KW - Pemphigoid

KW - Pemphigus

UR - http://www.scopus.com/inward/record.url?scp=85052955262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052955262&partnerID=8YFLogxK

U2 - 10.12688/f1000research.14474.1

DO - 10.12688/f1000research.14474.1

M3 - Review article

C2 - 30228865

AN - SCOPUS:85052955262

VL - 7

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 1360

ER -